Curto A, Albaladejo A. Implications of apixaban
for dental treatments. J Clin Exp
Dent. 2016;8(5):e611-4.
doi:10.4317/jced.53004
References
|
1. Mingarro-de-León
A, Chaveli-López B. Alternative to oral dicoumarin anticoagulants: Considerations in dental care.
J Clin Exp Dent. 2013;5:e273-8. |
|
|
|
|
|
2. Bashir
MA, Ray R, Sarda P, Li S, Corbett S. Determination
of a safe INR for joint injections in patients taking warfarin.
Ann R Coll Surg Engl.
2015;97:589-91. |
|
|
|
|
|
3. Rillig
A, Lin T, Plesman J, Heeger
CH, Lemes C, Metzner A,
et al. Apixaban, Rivaroxaban
and Dabigatran in Patients undergoing Atrial Fibrillation Ablation. J Cardiovasc
Electrophysiol. 2015 Oct 14. |
|
|
|
|
|
4. Imberti
D, Gallerani M, Manfredini
R. Therapeutic potential of apixaban in the
prevention of venous thromboembolism in patients
undergoing total knee replacement surgery. J Thromb
Thrombolysis. 2012;34:208-13. |
|
|
|
|
|
5.
Barón Esquivias G, Escolar Albaladejo
G, Zamorano JL, Betegón Nicolás L, Canal Fontcuberta C, de Salas-Cansado M, et al. Cost-effectiveness Analysis Comparing Apixaban and Acenocoumarol in
the Prevention of Stroke in Patients With Nonvalvular
Atrial Fibrillation in Spain. Rev Esp Cardiol (Engl Ed). 2015;68:680-90. |
|
|
|
|
|
6. Lanitis
T, Cotté FE, Gaudin AF, Kachaner I, Kongnakorn T,
Durand-Zaleski I. Stroke prevention in patients
with atrial fibrillation in France: comparative
cost-effectiveness of new oral anticoagulants (apixaban,
dabigatran, and rivaroxaban),
warfarin, and aspirin. J Med Econ. 2014;17:587-98. |
|
|
|
|
|
7. Budovich
A, Zargarova O, Nogid A.
Role of Apixaban (Eliquis)
in the Treatment And Prevention of Thromboembolic
Disease. Pharm Ther. 2013;38:206-31. PMid:23785225 |
|
|
|
|
|
8. Frost C, Nepal S, Wang
J, Schuster A, Byon W, Boyd RA. Safety,
pharmacokinetics and pharmacodynamics of multiple
oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013;76:776-86. |
|
|
|
|
|
9. Frost C, Wang J, Nepal
S, Schuster A, Barrett YC, Mosqueda-Garcia
R. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br
J Clin Pharmacol. 2013;75:476-87. |
|
|
|
|
|
10. Steiner T, Böhm M, Dichgans M, Diener HC, Ell C, Endres M, et
al. Recommendations for the emergency management of complications associated
with the new direct oral anticoagulants (DOACs), apixaban,
dabigatran and rivaroxaban.
Clin Res Cardiol. 2013;102:399-412. |
|
|
|
|
|
11. Connors JM. Antidote
for Factor Xa Anticoagulants. N Engl
J Med. 2015;25:2471-2. |
|
|
|
|
|
12.
Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E,
Roquer J, Reverter JC, Sanz VV. Reversal of Apixaban
Induced Alterations in Hemostasis by Different
Coagulation Factor Concentrates: Significance of Studies In Vitro with
Circulating Human Blood. PloS one. 2013;8:e78696. |
|
|
|
|
|
13. Kanemoto
M, Ikeda Y, Fujii T. How to Avoid Adverse Events
During Apixaban Therapy in Patients With Atrial Fibrillation. Circ J. 2015;12:2539-40. |
|
|
|
|
|
14.
Osanai H, Ajioka M, Masutomi T, Kuwayama T, Ishihama S, Sakamato Y, et al. Measurement of Anti-Factor Xa
Activity in Patients on Apixaban for Non-Valvular Atrial Fibrillation. Circ J. 2015;12:2584-90. |
|
|
|
|
|
15. Becker RC, Yang H,
Barrett Y, Mohan P, Wang J, Wallentin L, et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an
oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis. 2011;32:183-7. |
|
|
|
|
|
16.
Kanemoto M, Kuhara H, Ueda T, Shinohara T, Oda T, Nakao F, et al. Association
of apixaban therapy and prothrombin
time in patients with atrial fibrillation. Circ J. 2014;78:2651-6. |
|
|
|
|
|
17. Cheung YW, Barco S, Hutten BA, Meijers JC,
Middeldorp S, Coppens M.
In vivo increase in thrombin generation by four-factor prothrombin
complex concentrate in apixaban-treated healthy
volunteers. J
Thromb Haemost. 2015;13:1799-805. |
|
|
|
|
|
18. Dale BJ, Chan NC, Eikelboom JW. Laboratory measurement of the direct oral
anticoagulants. Br
J Haematol. 2016;172:315-36. |
|
|
|
|
|
19. Cuker A, Husseinzadeh H. Laboratory measurement
of the anticoagulant activity of edoxaban: a systematic
review. J Thromb Thrombolysis.
2015;39:288-94. |
|
|
|
|
|
20. Dale BJ, Ginsberg JS,
Johnston M, Hirsh J, Weitz JI, Eikelboom
JW. Comparison of the effects of apixaban and rivaroxaban on prothrombin and
activated partial thromboplastin times using
various reagents. J
Thromb Haemost. 2014;12:1810-5. |
|
|
|
|
|
21. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring
M. Dabigatran etexilate--a
novel, reversible, oral direct thrombin inhibitor: interpretation of
coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116-27. |
|
|
|
|
|
22.
Martínez-López F, O-ate-Sánchez R, Arrieta-Blanco JJ, O-ate-Cabrerizo D,
Cabrerizo-Merino MD. Clinical
diseases with thrombotic risk and their pharmacologycal
treatment: how they change the therapeutic attitude in dental treatments. Med
Oral Patol Oral Cir Bucal.
2013;18:e888-95. |
|
|
|
|
|
23. Spyropoulos
AC, Douketis JD. How I treat anticoagulated
patients undergoing an elective pro-cedure or
surgery. Blood. 2012;120:2954-62. |
|
|
|
|
|
24. Firriolo
FJ, Hupp WS. Beyond warfarin:
the new generation of oral anticoagulants and their implications for the
management of dental patients. Oral Surg Oral Med
Oral Pathol Oral Radiol.
2012;113:431–41. |
|
|
|
|
|
25. Schulman S, Crowther MA. How I treat anticoagulants in 2012: new and
old anticoagulants, and when and how to switch. Blood. 2012;119:3016–23. |
|
|
|
|
|
26. Little JW. New oral
anticoagulants: will they replace warfarin? Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:575-80. |
|
|
|
|
|
27.
Cardona-Tortajada F, Sainz-Gómez E, Figuerido-Garmendia J, de Robles-Adsuar
AL, Morte-Casabó A, Giner-Muñoz F, et al. Dental extractions in patients on antiplatelet
therapy. A study conducted by the Oral Health Department of the Navarre
Health Service (Spain). Med Oral Patol
Oral Cir Bucal. 2009;14:e588-92. |
|
|
|
|
|
28. Faraoni
D, Samama CM, Ranucci M,
Dietrich W, Levy JH. Perioperative management of
patients receiving new oral anticoagulants: an international survey. Clin Lab Med. 2014;34:637-54. |
|
|
|
|
|
29. Hankey
GJ, Norrving B, Hacke W,
Steiner T. Management of acute stroke in patients taking novel oral anticoagulants.
Int J Stroke. 2014;9:627-32. |
|
|
|
|
|
30. Lai A, Davidson N,
Galloway SW, Thachil J. Perioperative
management of patients on new oral anticoagulants. Br J Surg. 2014;101:742-9. |
|
|
|
|
|
31. Dincq
AS, Lessire S, Douxfils
J, Dogné JM, Gourdin M, Mullier F. Management of non-vitamin K antagonist oral
anticoagulants in the perioperative setting. Biomed Res Int. 2014;2014:385014. |
|
|
|
|
|
32. Baron TH, Kamath PS, McBane RD.
Management of antithrombotic therapy in patients undergoing invasive
procedures. N Engl J Med. 2013;368:2113-24. |
|
33. Sié P, Samama CM, Godier A, Rosencher N, Steib A, Llau JV, et al. Surgery and invasive procedures in patients
on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the
Working Group on Perioperative Haemostasis
and the French Study Group on Thrombosis and Haemostasis.
Arch Cardiovasc Dis. 2011;104:669-76.
https:/doi.org/10.1016/j.acvd.2011.09.001
PMid:22152517